nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenoxybenzamine—CALM1—autonomic nervous system—Gilles de la Tourette syndrome	0.048	0.18	CbGeAlD
Phenoxybenzamine—Diphenylpyraline—SLC6A3—Gilles de la Tourette syndrome	0.0108	0.354	CrCbGaD
Phenoxybenzamine—ADRA1B—nervous system—Gilles de la Tourette syndrome	0.0102	0.0381	CbGeAlD
Phenoxybenzamine—ADRA1D—nervous system—Gilles de la Tourette syndrome	0.00995	0.0373	CbGeAlD
Phenoxybenzamine—ADRA1B—central nervous system—Gilles de la Tourette syndrome	0.0098	0.0367	CbGeAlD
Phenoxybenzamine—ADRA1D—central nervous system—Gilles de la Tourette syndrome	0.00958	0.0359	CbGeAlD
Phenoxybenzamine—CALM3—midbrain—Gilles de la Tourette syndrome	0.00944	0.0353	CbGeAlD
Phenoxybenzamine—ADRA1B—brain—Gilles de la Tourette syndrome	0.00778	0.0291	CbGeAlD
Phenoxybenzamine—ADRA1D—brain—Gilles de la Tourette syndrome	0.00761	0.0285	CbGeAlD
Phenoxybenzamine—SLC22A1—nervous system—Gilles de la Tourette syndrome	0.00751	0.0281	CbGeAlD
Phenoxybenzamine—CALM2—midbrain—Gilles de la Tourette syndrome	0.00741	0.0278	CbGeAlD
Phenoxybenzamine—CALM1—midbrain—Gilles de la Tourette syndrome	0.00738	0.0276	CbGeAlD
Phenoxybenzamine—SLC22A1—central nervous system—Gilles de la Tourette syndrome	0.00723	0.0271	CbGeAlD
Phenoxybenzamine—SLC22A3—nervous system—Gilles de la Tourette syndrome	0.00718	0.0269	CbGeAlD
Phenoxybenzamine—SLC22A3—central nervous system—Gilles de la Tourette syndrome	0.00691	0.0259	CbGeAlD
Phenoxybenzamine—ADRA2C—midbrain—Gilles de la Tourette syndrome	0.00663	0.0248	CbGeAlD
Phenoxybenzamine—Modafinil—SLC6A3—Gilles de la Tourette syndrome	0.00615	0.201	CrCbGaD
Phenoxybenzamine—CALM2—nervous system—Gilles de la Tourette syndrome	0.00609	0.0228	CbGeAlD
Phenoxybenzamine—CALM1—nervous system—Gilles de la Tourette syndrome	0.00607	0.0227	CbGeAlD
Phenoxybenzamine—CALM3—brain—Gilles de la Tourette syndrome	0.00593	0.0222	CbGeAlD
Phenoxybenzamine—CALM2—central nervous system—Gilles de la Tourette syndrome	0.00587	0.022	CbGeAlD
Phenoxybenzamine—CALM1—central nervous system—Gilles de la Tourette syndrome	0.00584	0.0219	CbGeAlD
Phenoxybenzamine—SLC22A1—brain—Gilles de la Tourette syndrome	0.00574	0.0215	CbGeAlD
Phenoxybenzamine—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.00572	0.0214	CbGeAlD
Phenoxybenzamine—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.0055	0.0206	CbGeAlD
Phenoxybenzamine—SLC22A3—brain—Gilles de la Tourette syndrome	0.00548	0.0205	CbGeAlD
Phenoxybenzamine—ADRA2C—nervous system—Gilles de la Tourette syndrome	0.00545	0.0204	CbGeAlD
Phenoxybenzamine—Benzphetamine—SLC6A3—Gilles de la Tourette syndrome	0.00533	0.174	CrCbGaD
Phenoxybenzamine—Atomoxetine—SLC6A3—Gilles de la Tourette syndrome	0.00529	0.173	CrCbGaD
Phenoxybenzamine—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.00529	0.0198	CbGeAlD
Phenoxybenzamine—ADRA2C—central nervous system—Gilles de la Tourette syndrome	0.00524	0.0196	CbGeAlD
Phenoxybenzamine—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00474	0.00675	CbGpPWpGaD
Phenoxybenzamine—CALM2—brain—Gilles de la Tourette syndrome	0.00466	0.0174	CbGeAlD
Phenoxybenzamine—CALM1—brain—Gilles de la Tourette syndrome	0.00464	0.0174	CbGeAlD
Phenoxybenzamine—ADRA2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00438	0.00623	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.00437	0.00623	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—brain—Gilles de la Tourette syndrome	0.00437	0.0164	CbGeAlD
Phenoxybenzamine—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.00435	0.0163	CbGeAlD
Phenoxybenzamine—ADRB2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00432	0.00615	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00425	0.00606	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.00418	0.0157	CbGeAlD
Phenoxybenzamine—ADRA2C—brain—Gilles de la Tourette syndrome	0.00416	0.0156	CbGeAlD
Phenoxybenzamine—ADRA2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00409	0.00582	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00405	0.00576	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00402	0.00573	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00395	0.00563	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00393	0.00559	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00361	0.00513	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00357	0.00509	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0035	0.00498	CbGpPWpGaD
Phenoxybenzamine—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00342	0.0128	CbGeAlD
Phenoxybenzamine—ADRA2A—brain—Gilles de la Tourette syndrome	0.00332	0.0124	CbGeAlD
Phenoxybenzamine—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00332	0.00473	CbGpPWpGaD
Phenoxybenzamine—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00329	0.0123	CbGeAlD
Phenoxybenzamine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00307	0.00437	CbGpPWpGaD
Phenoxybenzamine—Atomoxetine—HTR2A—Gilles de la Tourette syndrome	0.00304	0.0992	CrCbGaD
Phenoxybenzamine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00286	0.00407	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00256	0.00365	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00228	0.00325	CbGpPWpGaD
Phenoxybenzamine—SLC22A3—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00222	0.00316	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00176	0.0025	CbGpPWpGaD
Phenoxybenzamine—SLC22A2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00172	0.00245	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00171	0.00243	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00171	0.00243	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00166	0.00236	CbGpPWpGaD
Phenoxybenzamine—SLC22A1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.0016	0.00228	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.0016	0.00227	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00159	0.00226	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00159	0.00226	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00157	0.00223	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00155	0.00221	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00155	0.0022	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00154	0.00219	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00152	0.00217	CbGpPWpGaD
Phenoxybenzamine—SLC22A3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00152	0.00216	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00151	0.00214	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00148	0.00211	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00146	0.00208	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00146	0.00208	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00144	0.00206	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00144	0.00205	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00144	0.00205	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00144	0.00204	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00142	0.00202	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00142	0.00202	CbGpPWpGaD
Phenoxybenzamine—SLC22A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00139	0.00198	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00136	0.00194	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00136	0.00194	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00134	0.00191	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00134	0.00191	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00132	0.00188	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00132	0.00188	CbGpPWpGaD
Phenoxybenzamine—SLC22A2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00132	0.00188	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0013	0.00186	CbGpPWpGaD
Phenoxybenzamine—SLC22A1—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.0013	0.00185	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.0013	0.00185	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0013	0.00185	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00129	0.00183	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00127	0.00181	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00126	0.00179	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00126	0.00179	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00125	0.00178	CbGpPWpGaD
Phenoxybenzamine—CALM3—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00124	0.00176	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00123	0.00176	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00123	0.00175	CbGpPWpGaD
Phenoxybenzamine—SLC22A1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00123	0.00175	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00121	0.00173	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00121	0.00173	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0012	0.00171	CbGpPWpGaD
Phenoxybenzamine—CALM2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.0012	0.00171	CbGpPWpGaD
Phenoxybenzamine—CALM1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.0012	0.00171	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.0012	0.0017	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00117	0.00167	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00117	0.00167	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00117	0.00166	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00115	0.00164	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00115	0.00163	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00113	0.00161	CbGpPWpGaD
Phenoxybenzamine—SLC22A3—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00113	0.00161	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00111	0.00159	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00111	0.00159	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00111	0.00158	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00109	0.00155	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00108	0.00153	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00107	0.00152	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00106	0.00151	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00104	0.00148	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00104	0.00147	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00103	0.00147	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00102	0.00146	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00101	0.00143	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00101	0.00143	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.001	0.00143	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.001	0.00143	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000992	0.00141	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000992	0.00141	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000967	0.00138	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000954	0.00136	CbGpPWpGaD
Phenoxybenzamine—SLC22A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000953	0.00136	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000952	0.00136	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00095	0.00135	CbGpPWpGaD
Phenoxybenzamine—CALM3—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00095	0.00135	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000939	0.00134	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000939	0.00134	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000936	0.00133	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000933	0.00133	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Metabolism—HDC—Gilles de la Tourette syndrome	0.000927	0.00132	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000924	0.00132	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000924	0.00132	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000924	0.00132	CbGpPWpGaD
Phenoxybenzamine—CALM2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000919	0.00131	CbGpPWpGaD
Phenoxybenzamine—CALM1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000919	0.00131	CbGpPWpGaD
Phenoxybenzamine—SLC22A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000889	0.00127	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000875	0.00125	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000861	0.00123	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000861	0.00123	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00085	0.00121	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000845	0.0012	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000821	0.00117	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000821	0.00117	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000804	0.00115	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000792	0.00113	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000785	0.00112	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000765	0.00109	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000763	0.00109	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000763	0.00109	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.000753	0.00107	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000726	0.00103	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00071	0.00101	CbGpPWpGaD
Phenoxybenzamine—SLC22A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000708	0.00101	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000703	0.001	CbGpPWpGaD
Phenoxybenzamine—CALM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.000687	0.000979	CbGpPWpGaD
Phenoxybenzamine—CALM2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000665	0.000947	CbGpPWpGaD
Phenoxybenzamine—CALM1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000665	0.000947	CbGpPWpGaD
Phenoxybenzamine—SLC22A1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00066	0.00094	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000656	0.000934	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000653	0.00093	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000648	0.000923	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000647	0.000922	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000629	0.000896	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000613	0.000872	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000603	0.000858	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000588	0.000838	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000586	0.000835	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000585	0.000833	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000578	0.000822	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000571	0.000813	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000568	0.000809	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000561	0.000798	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000546	0.000778	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000538	0.000766	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000535	0.000762	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000532	0.000758	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000531	0.000757	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000531	0.000755	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000529	0.000753	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000525	0.000747	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000522	0.000744	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000522	0.000744	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000516	0.000734	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000509	0.000725	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000498	0.000708	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000496	0.000707	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000494	0.000704	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000488	0.000695	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000486	0.000693	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000482	0.000686	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00048	0.000684	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000478	0.00068	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000474	0.000675	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000474	0.000675	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000464	0.00066	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000449	0.000639	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000444	0.000632	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000442	0.000629	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000434	0.000618	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000432	0.000615	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000431	0.000614	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000421	0.0006	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00041	0.000584	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000403	0.000574	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000401	0.000572	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000392	0.000559	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000391	0.000557	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000373	0.000531	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000371	0.000528	CbGpPWpGaD
Phenoxybenzamine—CALM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000368	0.000524	CbGpPWpGaD
Phenoxybenzamine—ADRB2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000366	0.000521	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000365	0.000519	CbGpPWpGaD
Phenoxybenzamine—CALM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000357	0.000508	CbGpPWpGaD
Phenoxybenzamine—CALM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000356	0.000507	CbGpPWpGaD
Phenoxybenzamine—CALM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000356	0.000507	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000348	0.000495	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000346	0.000493	CbGpPWpGaD
Phenoxybenzamine—CALM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000345	0.000492	CbGpPWpGaD
Phenoxybenzamine—CALM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000345	0.000492	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000341	0.000485	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000337	0.000481	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000337	0.000479	CbGpPWpGaD
Phenoxybenzamine—CALM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000333	0.000474	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000332	0.000473	CbGpPWpGaD
Phenoxybenzamine—CALM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000322	0.000458	CbGpPWpGaD
Phenoxybenzamine—CALM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000322	0.000458	CbGpPWpGaD
Phenoxybenzamine—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.000321	0.000457	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000314	0.000448	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000314	0.000448	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000314	0.000447	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00031	0.000441	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000309	0.000441	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000305	0.000434	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000303	0.000431	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000301	0.000428	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000293	0.000417	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000289	0.000411	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000285	0.000405	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000284	0.000404	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000281	0.0004	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00028	0.000399	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00028	0.000399	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000275	0.000391	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000265	0.000378	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000261	0.000372	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000256	0.000365	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000255	0.000364	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000249	0.000354	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000238	0.000339	CbGpPWpGaD
Phenoxybenzamine—CALM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000233	0.000332	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000232	0.00033	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000231	0.000329	CbGpPWpGaD
Phenoxybenzamine—CALM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000225	0.000321	CbGpPWpGaD
Phenoxybenzamine—CALM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000225	0.000321	CbGpPWpGaD
Phenoxybenzamine—ADRA1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00022	0.000314	CbGpPWpGaD
Phenoxybenzamine—CALM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000217	0.000309	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000215	0.000307	CbGpPWpGaD
Phenoxybenzamine—CALM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000211	0.0003	CbGpPWpGaD
Phenoxybenzamine—CALM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00021	0.000299	CbGpPWpGaD
Phenoxybenzamine—CALM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00021	0.000299	CbGpPWpGaD
Phenoxybenzamine—CALM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000204	0.000291	CbGpPWpGaD
Phenoxybenzamine—CALM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000204	0.000291	CbGpPWpGaD
Phenoxybenzamine—ADRA2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000199	0.000283	CbGpPWpGaD
Phenoxybenzamine—CALM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000196	0.00028	CbGpPWpGaD
Phenoxybenzamine—ADRB2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000196	0.000279	CbGpPWpGaD
Phenoxybenzamine—CALM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00019	0.000271	CbGpPWpGaD
Phenoxybenzamine—CALM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00019	0.000271	CbGpPWpGaD
Phenoxybenzamine—ADRA2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000186	0.000264	CbGpPWpGaD
Phenoxybenzamine—ADRA1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000183	0.00026	CbGpPWpGaD
Phenoxybenzamine—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000162	0.000231	CbGpPWpGaD
Phenoxybenzamine—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000151	0.000215	CbGpPWpGaD
Phenoxybenzamine—CALM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000138	0.000196	CbGpPWpGaD
Phenoxybenzamine—CALM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000133	0.00019	CbGpPWpGaD
Phenoxybenzamine—CALM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000133	0.00019	CbGpPWpGaD
